Healthcare
Live Price
Offline$10.09
-0.49% today
1Y Change
-32.49%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DENTSPLY SIRONA Inc. (XRAY) is a Healthcare stock with a market cap of $2.24B and listed on NASDAQ. The stock last traded around $10.09 and down 32.5% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -3.0%, EPS growth of +33.0%, a dividend yield of 5.7%. What stands out right now is revenue -3.0%, EPS +33.0%, free cash flow -63.0% with operating margin 6.8% and ROIC 5.7%. The dividend matters to the case here, with a current yield around 5.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines XRAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XRAY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XRAY Max Drawdown
-42.79%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XRAY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.2B
+7.9% YoY
FY Net Income
$411.0M
+143.3% YoY
Free Cash Flow
$515.0M
+39.9% YoY
Revenue Growth
-3.0%
EPS Growth
+33.0%
Gross Margin
50.0%
Net Margin
-16.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.7B | 3.8B | 4.0B | 3.9B | 4.2B |
| Gross Profit | 1.8B | 2.0B | 2.1B | 2.1B | 2.3B |
| Operating Income | 252M | -879M | -85M | -937M | 608M |
| EBITDA | -46M | -518M | 249M | -662M | 952M |
| Net Income | -598M | -910M | -132M | -950M | 411M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 326M | 272M | 334M | 365M | 339M |
| Total Assets | 5.4B | 5.8B | 7.4B | 7.6B | 9.2B |
| Total Liabilities | 4.1B | 3.8B | 4.1B | 3.8B | 4.2B |
| Shareholder Equity | 1.3B | 1.9B | 3.3B | 3.8B | 5.0B |
| Total Debt | 2.5B | 2.3B | 2.3B | 2.1B | 2.3B |
| Net Debt | 2.1B | 2.0B | 2.0B | 1.8B | 2.0B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
657M
+27.1% YoY
Capital Expenditures
142M
+4.7% YoY
Free Cash Flow
515M
+39.9% YoY
Key ratios
Gross Margin
50.0%
Operating Margin
6.8%
Net Margin
-16.3%
ROE
-35.2%
Debt / Equity
1.84x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.